Windtree Therapeutics Appoints New CMO, Elects Director

Ticker: WINTW · Form: 8-K · Filed: Sep 8, 2025 · CIK: 946486

Windtree Therapeutics Inc /De/ 8-K Filing Summary
FieldDetail
CompanyWindtree Therapeutics Inc /De/ (WINTW)
Form Type8-K
Filed DateSep 8, 2025
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-election, personnel-change

TL;DR

Windtree names new CMO, adds a director to the board.

AI Summary

Windtree Therapeutics, Inc. announced on September 2, 2025, the appointment of Dr. Paul J. McNelis as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers.

Why It Matters

These executive changes and board appointments can signal shifts in the company's strategic direction and leadership, potentially impacting its future development and financial performance.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.

Key Players & Entities

  • Windtree Therapeutics, Inc. (company) — Registrant
  • Dr. Paul J. McNelis (person) — Appointed Chief Medical Officer
  • Ms. Sarah E. Kelly (person) — Elected to Board of Directors
  • September 2, 2025 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer of Windtree Therapeutics?

Dr. Paul J. McNelis has been appointed as the new Chief Medical Officer.

Who has been elected to the Board of Directors at Windtree Therapeutics?

Ms. Sarah E. Kelly has been elected to the Board of Directors.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is September 2, 2025.

What other information is disclosed regarding executive officers in this filing?

The filing also discloses compensatory arrangements of certain officers.

In which state was Windtree Therapeutics, Inc. incorporated?

Windtree Therapeutics, Inc. was incorporated in Delaware.

Filing Stats: 399 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-09-08 17:16:02

Key Financial Figures

  • $0.001 — h registered Common Stock , par value $0.001 per share WINT OTCID Indicate by ch

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: September 8, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.